Literature DB >> 22509430

Host stem cells repopulate liver allografts: reverse chimerism.

Zhaoli Sun1, George Melville Williams.   

Abstract

Liver transplant has become life-saving therapy for thousands of patients with end stage liver disease in the United States, but chronic rejection and the toxicities of immunosuppression remain significant obstacles to the further expansion of this modality and "transplant tolerance" remains a central goal in the field. So we and others are looking for alternative post-transplant strategies. We set out to 'engineer' repopulation after transplantation in a strain combination [dark agouti (DA) to Lewis green fluorescent protein+ (LEW GFP+)] which rejects liver grafts strongly, a model that more closely resembles the situation in humans. Our central finding is purposeful manipulation of the immune response with low dose immunosuppression and liberation of stem cells for a very short period after transplantation results in long-term transplant acceptance by two mechanisms: transforming the liver (donor) to self (host) phenotype, and auto-suppression of the specific allograft response.

Entities:  

Keywords:  host bone marrow stem cells; liver transplant; plerixafor; rat; tacrolimus

Mesh:

Substances:

Year:  2011        PMID: 22509430      PMCID: PMC3321884          DOI: 10.4161/chim.2.4.19177

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  15 in total

1.  The immunosuppressive properties of mesenchymal stem cells.

Authors:  Georg Siegel; Richard Schäfer; Francesco Dazzi
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

Review 2.  Mesenchymal stem cells can affect solid organ allograft survival.

Authors:  Felix C Popp; Elke Eggenhofer; Philipp Renner; Edward K Geissler; Pompiliu Piso; Hans J Schlitt; Marc H Dahlke
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

Review 3.  Immune properties of mesenchymal stem cells.

Authors:  Panagiota A Sotiropoulou; Michael Papamichail
Journal:  Methods Mol Biol       Date:  2007

4.  Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination.

Authors:  T Okabayashi; A M Cameron; M Hisada; R A Montgomery; G M Williams; Z Sun
Journal:  Am J Transplant       Date:  2011-08-30       Impact factor: 8.086

5.  Host repopulation of endothelium.

Authors:  G M Williams; C A Krajewski; F J Dagher; A M ter Haar; J A Roth; G W Santos
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

6.  Host repopulation of the endothelium in allografts of kidneys and aorta.

Authors:  G M Williams; C A Alvarez
Journal:  Surg Forum       Date:  1969

Review 7.  Mixed chimerism and transplantation tolerance.

Authors:  A Benedict Cosimi; David H Sachs
Journal:  Transplantation       Date:  2004-03-27       Impact factor: 4.939

8.  Systemic chimerism in human female recipients of male livers.

Authors:  T E Starzl; A J Demetris; M Trucco; H Ramos; A Zeevi; W A Rudert; M Kocova; C Ricordi; S Ildstad; N Murase
Journal:  Lancet       Date:  1992-10-10       Impact factor: 79.321

9.  Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease.

Authors:  T E Starzl; A J Demetris; M Trucco; C Ricordi; S Ildstad; P I Terasaki; N Murase; R S Kendall; M Kocova; W A Rudert
Journal:  N Engl J Med       Date:  1993-03-18       Impact factor: 91.245

Review 10.  Immunological properties of mesenchymal stem cells and clinical implications.

Authors:  Shyam A Patel; Lauren Sherman; Jessian Munoz; Pranela Rameshwar
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-02-05       Impact factor: 4.291

View more
  1 in total

1.  Pharmacological Mobilization of Endogenous Bone Marrow Stem Cells Promotes Liver Regeneration after Extensive Liver Resection in Rats.

Authors:  Rujun Zhai; Yongchun Wang; Le Qi; George Melville Williams; Bin Gao; Guang Song; James F Burdick; Zhaoli Sun
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.